Marino, Mark
- Venturewell (no department on record)
From the FY2023 NIH awards this investigator leads as contact PI. The department is the award's.
FY2023 NIH rank #3,659
- Early Career
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID unavailableSearch this ID in NIH RePORTER
- ORCID iD
- No ORCID iD on recordA researcher can add one by claiming this profile.
- ScienceDex PI coverage
- FY2021 through FY2023Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2026.
NIH Funding · FY2023
Linked Award Amount
$2M
Full award amounts, FY2023
Award Records
3
Records listing this PI
Award-Linked Rank
#3,659
By linked amount among FY2023 PIs
Earliest Year Loaded
2021
ScienceDex PI coverage
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
FY2023 award records by amount
NIH award records listing Marino, Mark as a PI. Multi-PI records show the full award amount for context.
- 75N92022D00013-P00003-759202200004-1N02Contact PISUPPLEMENTAL FUNDS FOR RADX INDEPENDENT TEST ASSESSMENT PROGRAM FOR HEPATITIS C VIRUS - COMMERCIALIZATION CENTER$850Kaward amount
- 75N92022D00013-0-759202300003-1N02Contact PIRADX Independent Test Assessment Program for MPOX Lesion Panel - Commercialization Center$659.8Kaward amount
- 75N92022D00013-0-759202300001-1N02Contact PINCE FOR COMMERCIALIZATION CENTER TASK ORDER FOR CANCER SCREENING RESEARCH NETWORK$528.5Kaward amount
Award organization
Organizations that administered FY2023 awards listing Marino, Mark as a PI.
FY2023 award administered by Venturewell (MA).
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2021First NIH AwardVenturewell
- 2021$500K Cumulative Funding
- 2021$1M Cumulative Funding
- 2021$2M Cumulative Funding
- 2021$5M Cumulative Funding
- 2021$10M Cumulative Funding
- 2021$25M Cumulative Funding
- 2021Entered Top 50% NationallyRanked #20
- 2021Entered Top 25% NationallyRanked #20
- 2021Entered Top 10% NationallyRanked #20
- 2021Entered Top 5% NationallyRanked #20
- 2021Entered Top 1% NationallyRanked #20
- 2022$50M Cumulative Funding